Phaseline

Companies › Glaceum

Glaceum: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Immunology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Vutiglabridin–Phase 2Knee Osteoarthritis (Knee OA)Dec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06845553VutiglabridinPhase 2Knee Osteoarthritis (Knee OA)ImmunologyDec 2026

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Toll Biotech Co. Ltd. (Beijing) Ventus Therapeutics U.S. Navigator Medicines OrthoTrophix Resolve Therapeutics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.